Pacira Pharmaceuticals Inc

Most Recent

  • uploads///PCRX
    Company & Industry Overviews

    Pacira Pharmaceuticals’ Top Line Continues to Expand

    Pacira Pharmaceuticals (PCRX) is a specialty pharmaceutical company focused on bringing products to the market that are based on its proprietary DepoFoam technology.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    How Is Insys Therapeutics Positioned in H2 2018?

    Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.

    By Kenneth Smith
  • uploads///Chart  Developments
    Earnings Report

    A Look at Johnson & Johnson’s Major Developments in 1Q17

    As we discussed earlier, Johnson & Johnson’s 1Q17 segment-by-segment performance was positive across all of its segments. Now, let’s take a look at some of its major developments during 1Q17.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    What Are IBB’s Holdings’ Moving Averages?

    On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Pacira’s Strong 3Q15 Results Helped the Pharma Subgroup

    Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.